STAR Cape+BKM120 MBC With Brain Met

• Sponsor: US Oncology Research (Industry)
• Overall Status: Completed
• CT.gov ID: NCT02000882
• Collaborator: Novartis Pharmaceuticals (Industry)
• Enrollment: 10
• Location: 1
• Arm: 1
• Actual Duration (Months): 58
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This is a study to determine the safety and effectiveness of BKM120 plus capecitabine in breast cancer patients with brain metastases.

Both capecitabine and BMK120 have previously shown activity in patients with breast cancer. Like capecitabine, BMK120 is also effective in crossing the blood brain barrier making it a preferred candidate for its evaluation in patients with metastatic breast cancer (MBC).

Condition or Disease	Intervention/Treatment	Phase
Brain Metastases; Breast Cancer; Metastatic Breast Cancer	Drug: BKM120; Drug: capecitabine; Drug: Trastuzumab	Phase 2

Detailed Description

This is a Phase 2, multicenter, single-arm study to determine the safety and efficacy of BKM120 plus capecitabine in breast cancer patients with brain metastases. 40 patients will be included, who have either ER+/HER2-, HER2+ or triple negative breast cancer..

The Graded Prognostic Assessment (GPA) is a recently developed, validated prognostic score for patients with brain metastases. The Graded Prognostic Assessment will be utilized to evaluate efficacy in this clinical study.

Capecitabine is a prodrug which is enzymatically converted to 5-fluorouracil in its tumor target where it inhibits DNA synthesis and slows tumor growth. It is currently FDA approved for both colorectal and breast cancer. BMK120 is a pan phosphatidylinositol-3-kinase inhibitor being developed under IND# 102,823 by Novartis Corporation. As of September 2012 over 600 patients had been enrolled in fourteen separate Novartis sponsored monotherapy or combination therapy clinical studies of BMK120.

Phosphatidylinositol-3-kinase (PI3K) signaling regulates diverse cellular functions including cell proliferation, survival, translational regulation of protein synthesis, glucose metabolism, cell migration, and angiogenesis. PI3K signaling also serves a central role in the pathogenesis of numerous cancers.

Constitutive activation of PI3K signaling is known to be a critical step in mediating the transforming potential of oncogenes and tumor suppressors in many tumor types. Resistance to a variety of therapeutic interventions, including hormonal therapy, anti-HER2 therapies and chemotherapy can also be linked to constitutive activation of the PI3K pathway.

Preliminary data suggest that activation of the PI3K pathway is a predictor of a poor prognostic outcome in many cancer types. Thus, as a pan-PI3K inhibitor, BMK120 may provide a therapeutic benefit to patients with MBC. Both capecitabine and BMK120 have previously shown activity in patients with MBC. Like capecitabine, BMK120 is also effective in crossing the blood brain barrier making it a preferred candidate for its evaluation in patients with MBC.

Trastuzumab is a monoclonal antibody that targets the HER2 receptor which is overexpressed or amplified in approximately 20-25% of breast cancers. The clinical benefit of trastuzumab in women with metastatic breast cancer has been demonstrated in two pivotal studies.

Current clinical experience with BMK120 has shown that its most frequent adverse events (AEs) include fatigue, decreased appetite, diarrhea, hyperglycemia, nausea, rash and mood alteration disorders. Therefore patients will be closely monitored for fasting plasma glucose (FPG) HbA1c, and insulin C-peptide. Patients will also be frequently and routinely evaluated for mood disorders and disturbances. The remaining most frequent AEs will be detected by regular, frequent monitoring with symptomatic treatment to be provided as required.

Study Design

• Study Type: Interventional
• Actual Enrollment: 10 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Multicenter Single-arm Study of BKM120 Plus Capecitabine for Breast Cancer Patients With Brain Metastases
• Actual Study Start Date: May 29, 2014
• Actual Primary Completion Date: Mar 29, 2019
• Actual Study Completion Date: Mar 29, 2019

Arms and Interventions

Arm	Intervention/Treatment
Experimental: BKM120 plus Capecitabine BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120.	Drug: BKM120; Other Names: buparlisib ; Drug: capecitabine; Other Names: Xeloda ; Drug: Trastuzumab; Other Names: Herceptin

Outcome Measures

Primary Outcome Measures

1. Clinical Benefit Rate (CBR) [until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration]

   CBR in the patients following WBRT or SRS or both will be the primary endpoint and is calculated as the total number of responders (CR or PR, assessed by RECIST 1.1) plus stable disease greater than or equal to 24 weeks (CR + PR + SD ≥ 24 weeks) divided by the total number of evaluable patients. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Secondary Outcome Measures

1. Objective Response Rate (ORR) [until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration]

   To assess ORR (CR + PR) associated with BKM120 plus capecitabine in the central nervous system based on local investigator assessment. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

2. Median Time to Progression [until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration]

   To assess median time to progression (TTP) associated with BKM120 plus capecitabine.

3. Median Overall Survival [up to 2 years from date of patient registration]

   To determine median overall survival (OS) associated with BKM120 plus capecitabine.

4. Number of Treatment-related Serious AEs [until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration]

   To characterize the safety and tolerability of BKM120 plus capecitabine, with or without trastuzumab

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Age ≥ 18 years

2. Female

3. Histologically and/or cytologically confirmed diagnosis of inoperable metastatic breast cancer

4. ER+/HER2- OR HER2+ OR triple-negative breast cancer, assessed as ER-, PgR-, and HER2-negative by local laboratory testing; HER2 negative status (based on most recently analyzed biopsy) is defined as IHC status of 0, 1+ or 2+ (if IHC 2+, a negative FISH test is required, ie, HER2 FISH ratio < 2.0); ER-negative and PR-negative status is defined as ER and PgR <10% nuclei positive by IHC. HER2-positive status is defined as 3+ staining in ≥10% of cells by immunohistochemistry or a HER2/CEP17 ratio ≥2 or an average of ≥6 HER2 gene copies per cell by in situ hybridization (ISH)

5. At least one CNS lesion that is at least 5mm in size in at least one dimension in the setting of prior WBRT

• Prior WBRT is required and may have been administered at any time in patient's treatment history. Patients in the primary analysis will not have evidence of progression of disease following WBRT. However, patients whose brain metastases have progressed following WBRT are eligible. Patients must have completed WBRT at least 3 weeks prior to study entry.

• Prior SRS is allowed, but previous treatment of the 5mm target CNS lesion with SRS is not permitted

1. ECOG performance status ≤ 2

2. Adequate bone marrow function as shown by: ANC ≥ 1.5 x 109/L, Platelets ≥ 100 x 109/L, Hb >9 g/dL

3. Total calcium (corrected for serum albumin) within normal limits (biphosphonate use for malignant hypercalcemia control is not allowed)

4. Magnesium ≥ the lower limit of normal

5. Potassium within normal limits for the institution

6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range (or ≤ 3.0 x upper limit of normal (ULN) if liver metastases are present)

7. Serum bilirubin within normal range (or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin within normal range in patients with known Gilbert Syndrome)

8. Serum creatinine ≤ 1.5 x ULN or 24-hour clearance ≥ 50 mL/min

9. Serum amylase ≤ ULN

10. Serum lipase ≤ ULN

11. Fasting plasma glucose ≤ 120 mg/dL (6.7 mmol/L)

12. Negative serum pregnancy test within 72 hours before starting study treatment in women with childbearing potential

13. INR ≤ 2

14. Life expectancy > 12 weeks

15. Available tissue (blocks and/or slides) samples unless discussed in advance with study principal investigator

16. Patient is able to swallow and retain oral medication

17. Signed most recent patient informed consent form

18. Signed Patient Authorization Form

Exclusion Criteria:

1. Patient received prior treatment with a P13K inhibitor.

2. Patient with known hypersensitivity to BKM120, capecitabine, or their excipients.

3. Patient has evidence of impending herniation on baseline brain imaging.

4. Patient has evidence of diffuse leptomeningeal disease on brain MRI or by previously documented CSF.

5. Patient has acute or chronic liver, renal disease or pancreatitis (liver metastases are allowed)

6. Patients has a mood disorder as judged by the Investigator or a psychiatrist, or as a result of patient's mood assessment questionnaire (PHQ-9 and/or GAD-7):

• Medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (immediate risk of doing harm to others) or patients with active severe personality disorders (defined according to DSM- IV) are not eligible. Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug.

• ≥ CTCAE grade 3 anxiety

• Meets the cut-off score of ≥ 12 in the PHQ-9 or a cut-off of ≥ 15 in the GAD-7 mood scale, respectively, or selects a positive response of "1, 2, or 3" to question number 9 regarding potential for suicidal thoughts in the PHQ-9 (independent of the total score of the PHQ-9)

1. Patients has diarrhea ≥ CTCAE grade 2

2. Patients with uncontrolled hypertension defined as systolic blood pressure 170 or greater or diastolic blood pressure over 100.

3. Patient has active cardiac disease including any of the following:

• Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)

• QTc > 480 msec on screening ECG (using the QTcF formula)

• Angina pectoris that requires the use of anti-anginal medication

• Ventricular arrhythmias except for benign premature ventricular contractions

• Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication

• Conduction abnormality requiring a pacemaker

• Valvular disease with document compromise in cardiac function

• Symptomatic pericarditis

1. Patient has a history of cardiac dysfunction including any of the following:

• Myocardial infarction within the last 6 months, documented by persistent elevated cardiac enzymes or persistent regional wall abnormalities on assessment of LVEF function

• History of documented congestive heart failure (New York Heart Association functional classification III-IV)

• Documented cardiomyopathy

1. Patient has poorly controlled diabetes mellitus or steroid-induced diabetes mellitus

2. Patient has other concurrent severe and/or uncontrolled concomitant medical conditions (e.g., active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol

• Significant symptomatic deterioration of lung function. If clinically indicated, pulmonary function tests including measures of predicted lung volumes, DLco, O2 saturation at rest on room air should be considered to exclude pneumonitis or pulmonary infiltrates.

1. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). Patients with unresolved diarrhea will be excluded as previously indicated

2. Patient was treated with any hematopoietic colony-stimulating growth factors (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin or darbepoetin therapy, if initiated at least 2 weeks prior to enrollment, may be continued

3. Patient is currently receiving treatment with medication with a known risk to prolong the QT interval or inducing Torsades de Pointes and the treatment cannot either be discontinued or switched to a different medication prior to starting study drug.

4. Patients receiving chronic treatment with steroids or another immunosuppressive agent. Patients must have been off all corticosteroids (except for physiologic doses of hydrocortisone as replacement therapy) for at least 2 weeks prior to study entry.

• Note: Single doses, or topical applications (e.g. rash), inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intra-articular) are allowed.

1. Patient has taken herbal medications and certain fruits within 7 days prior to starting study drug. Herbal medications include, but are not limited to St. John's wort, Kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. Fruits include the CYP3A inhibitors Seville oranges, grapefruit, pummelos, or exotic citrus fruits. Regular orange juice is permitted.

2. Patient is currently treated with drugs known to be moderate and strong inhibitors or inducers of isoenzyme CYP3A, and the treatment cannot be discontinued or switched to a different medication prior to starting study drug. Please refer to Table 4-8 for a list of prohibited inhibitors and inducers of CYP3A (Please note that co-treatment with weak inhibitors of CYP3A is allowed).

3. Patient received chemotherapy or targeted anticancer therapy ≤ 3 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug, and have related side effects must recover to a grade 1 or less before starting the trial

4. Patient received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) with ≤ 5 effective half lives prior to starting study drug or who have not recovered from side effects of such therapy

5. Patient received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy

6. Patient underwent major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.

7. Patient is currently taking therapeutic doses of warfarin sodium or any other coumadin-derivative anticoagulant.

8. Patient is pregnant or breast feeding or is of reproductive potential and not employing an effective method of birth control.

• Note: Double barrier contraceptives must be used through the trial by both sexes. Oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this study. Women of child-bearing potential, defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months), must have a negative serum pregnancy test ≤ 72 hours prior to initiating treatment.

• Note: Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or six months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: and estradiol < 20 pg/mL] or have had surgical bilateral oophorectomy (with or without hysterectomy) at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

• Note: Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use highly effective contraception during treatment for 4 weeks (5 T1/2) after stopping treatment. The highly effective contraception is defined as either:

1. True abstinence: When this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

1. Sterilization: have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.

2. Male partner sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate). For female subjects on the study, the vasectomised male partner should be the sole partner for that patient.

3. Use of a combination of any two of the following (a+b):

1. Placement of an intrauterine device (IUD) or intrauterine system (IUS)

2. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

• Oral contraception, injected or implanted hormonal methods are not allowed as BKM120 potentially decreases the effectiveness of hormonal contraceptives.

1. Patient has known diagnosis of human immunodeficiency virus (HIV) infection

2. Patient has history of another malignancy within 5 years, except cured basal cell carcinoma of the skin or excised carcinoma in situ of the cervix

3. Patient is unable or unwilling to abide by the study protocol or cooperate fully with the investigator

4. Patient is concurrently using other approved or investigational antineoplastic agent.

5. Patient taking or needing enzyme-inducing anti-epileptic medication.

6. Patient has an acute viral hepatitis or a history of chronic or active HBV or HCV infection

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Please contact Zuzanne Bristow for list of sites	Multiple Locations	Texas	United States

Sponsors and Collaborators

• US Oncology Research
• Novartis Pharmaceuticals

Investigators

• Principal Investigator: Joyce A. O'Shaughnessy, MD, US Oncology Research, McKesson Specialty Health
• Principal Investigator: Morris D. Groves, MD, JD, US Oncology Research, McKesson Specialty Health

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Jun 24, 2016

More Information

Publications

None provided.

• Responsible Party: US Oncology Research
• ClinicalTrials.gov Identifier: NCT02000882
• Other Study ID Numbers: 11025; CBKM120ZUS39T
• First Posted: Dec 4, 2013
• Last Update Posted: Feb 7, 2022
• Last Verified: Jan 1, 2022

• Keywords provided by US Oncology Research: Breast Cancer; Triple Negative Breast Cancer; Brain Metastases; Capecitabine; Metastatic Breast Cancer
• Additional relevant MeSH terms: Breast Neoplasms; Neoplasm Metastasis; Brain Neoplasms; Capecitabine; Trastuzumab

Study Results

Participant Flow

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Period Title: Overall Study
STARTED	10
COMPLETED	4
NOT COMPLETED	6

Baseline Characteristics

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Overall Participants	10
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	50.1 (11.0)
Sex: Female, Male (Count of Participants)
Female	10 100%
Male	0 0%
Race/Ethnicity, Customized (Count of Participants)
Asian	1 10%
Black	2 20%
Caucasian	6 60%
Hispanic	1 10%
Region of Enrollment (Count of Participants)
United States	10 100%

Outcome Measures

1. Primary Outcome

Title	Clinical Benefit Rate (CBR)
Description	CBR in the patients following WBRT or SRS or both will be the primary endpoint and is calculated as the total number of responders (CR or PR, assessed by RECIST 1.1) plus stable disease greater than or equal to 24 weeks (CR + PR + SD ≥ 24 weeks) divided by the total number of evaluable patients. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time Frame	until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Measure Participants	10
Number (90% Confidence Interval) [proportion of patients with CBR]	0.1

2. Secondary Outcome

Title	Objective Response Rate (ORR)
Description	To assess ORR (CR + PR) associated with BKM120 plus capecitabine in the central nervous system based on local investigator assessment. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Time Frame	until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Measure Participants	10
Number (90% Confidence Interval) [proportion of patients with ORR]	0.0

3. Secondary Outcome

Title	Median Time to Progression
Description	To assess median time to progression (TTP) associated with BKM120 plus capecitabine.
Time Frame	until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Measure Participants	10
Median (Standard Deviation) [months]	5.59 (4.64)

4. Secondary Outcome

Title	Median Overall Survival
Description	To determine median overall survival (OS) associated with BKM120 plus capecitabine.
Time Frame	up to 2 years from date of patient registration

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Measure Participants	10
Median (Standard Deviation) [months]	11.135 (6.302)

5. Secondary Outcome

Title	Number of Treatment-related Serious AEs
Description	To characterize the safety and tolerability of BKM120 plus capecitabine, with or without trastuzumab
Time Frame	until disease progression (assessed by RECIST 1.1), unacceptable toxicity, death, or discontinuation from study for any other reason, up to 2 years from date of patient registration

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
Measure Participants	10
Number [Number of Treatment-related Serious AEs]	7

Adverse Events

Time Frame	until 30 days after last dose of patient's study treatment, for up 2 years from date of registration (enrollment into study)
Arm/Group Title	BKM120 Plus Capecitabine
Arm/Group Description	BKM120 will be administered at a dose of 100 mg orally (PO) daily. Capecitabine will be administered at a dose of 1000 mg/m2 orally (PO) twice a day (rounded down to the nearest 500 mg pill) 14 days on and 7 days off. For patients with HER2+ MBC only, standard every 3-weekly trastuzumab (6 mg/kg IV) will be added to the capecitabine/BKM120. BKM120 capecitabine Trastuzumab
All Cause Mortality
	BKM120 Plus Capecitabine
	Affected / at Risk (%)	# Events
Total	7/10 (70%)
Serious Adverse Events
	BKM120 Plus Capecitabine
	Affected / at Risk (%)	# Events
Total	7/10 (70%)
Gastrointestinal disorders
Colitis	1/10 (10%)	1
Dysphagia	1/10 (10%)	1
Nausea	1/10 (10%)	1
Vomiting	1/10 (10%)	1
General disorders
Weakness generalized	1/10 (10%)	1
Metabolism and nutrition disorders
Hypokalemia	1/10 (10%)	1
Hyponatremia	1/10 (10%)	1
Musculoskeletal and connective tissue disorders
Knee Pain	1/10 (10%)	1
Nervous system disorders
Epilepsy	1/10 (10%)	1
Seizure	2/10 (20%)	2
Renal and urinary disorders
Urinary tract infection	2/10 (20%)	2
Skin and subcutaneous tissue disorders
Rash erythematous	1/10 (10%)	1
Other (Not Including Serious) Adverse Events
	BKM120 Plus Capecitabine
	Affected / at Risk (%)	# Events
Total	10/10 (100%)
Blood and lymphatic system disorders
Anemia	1/10 (10%)	1
Hypovolemia	1/10 (10%)	1
Leukopenia	1/10 (10%)	1
Neutropenia	1/10 (10%)	1
Ear and labyrinth disorders
Disorder ear	1/10 (10%)	1
Eye disorders
Blurred vision	2/10 (20%)	2
Disorder eye	1/10 (10%)	1
Eye floaters	1/10 (10%)	1
Vision abnormal	1/10 (10%)	1
Visual disturbance	1/10 (10%)	1
Gastrointestinal disorders
Abdominal Pain	1/10 (10%)	1
Anorexia	5/10 (50%)	5
Canker sore oral	1/10 (10%)	1
Constipation	2/10 (20%)	2
Cramp abdominal	1/10 (10%)	1
Diarrhea	4/10 (40%)	4
Dry mouth	1/10 (10%)	1
Gastritis	1/10 (10%)	1
Hemorrhoids	1/10 (10%)	1
Mucositis oral	4/10 (40%)	4
Nausea	6/10 (60%)	6
Pancreatitis	1/10 (10%)	1
Spasm oropharyngeal	1/10 (10%)	1
Stomatitis	1/10 (10%)	1
Vomiting	5/10 (50%)	5
General disorders
Falling down	2/10 (20%)	2
Fatigue	5/10 (50%)	5
Hand-foot syndrome	1/10 (10%)	1
Legs restless	1/10 (10%)	1
Taste alteration	1/10 (10%)	1
Immune system disorders
Allergic reaction	1/10 (10%)	1
Infections and infestations
Thrush	1/10 (10%)	1
Investigations
Bilirubin increased	2/10 (20%)	2
Creatinine serum increased	1/10 (10%)	1
Metabolism and nutrition disorders
ALT increased	2/10 (20%)	2
Amylase increased	1/10 (10%)	1
AST increased	2/10 (20%)	2
Dehyrdration	2/10 (20%)	2
Growth accelerated	1/10 (10%)	1
Hyperglycemia	1/10 (10%)	1
Hypocalcemia	1/10 (10%)	1
Hypokalemia	5/10 (50%)	5
Hyponatremia	2/10 (20%)	2
Lipase increased	1/10 (10%)	1
Potassium deficiency	1/10 (10%)	1
Musculoskeletal and connective tissue disorders
Muscle weakness	1/10 (10%)	1
Nervous system disorders
Dizziness	1/10 (10%)	1
Dysgeusia	1/10 (10%)	1
Edema cerebral	1/10 (10%)	1
Headache	2/10 (20%)	2
Neuropathy	1/10 (10%)	1
Numbness	1/10 (10%)	1
Somnolence	1/10 (10%)	1
Tremor	1/10 (10%)	1
Psychiatric disorders
Agitation	1/10 (10%)	1
Depression	1/10 (10%)	1
Emotional lability	1/10 (10%)	1
Insomnia	3/10 (30%)	3
Renal and urinary disorders
Incontinence urinary	1/10 (10%)	1
Renal function abnormal	1/10 (10%)	1
Urinary tract infection	4/10 (40%)	4
Respiratory, thoracic and mediastinal disorders
Dyspnea	1/10 (10%)	1
Epistaxis	1/10 (10%)	1
Skin and subcutaneous tissue disorders
Facial swelling	1/10 (10%)	1
Palmar-plantar erythrodysesthesia	3/10 (30%)	3
Rash	3/10 (30%)	3
Vascular disorders
Hypertension	1/10 (10%)	1

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.